We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





New Long-Acting Antibody Combination Treatment Could Give COVID-19 Immunity

By HospiMedica International staff writers
Posted on 28 Dec 2020
Print article
Illustration
Illustration
Researchers have begun two clinical trials for testing a long-acting antibody combination treatment to protect against COVID-19.

In the STORM CHASER study, researchers from the University College London Hospitals NHS Foundation Trust (UCLH; London, UK) have recruited 10 participants to date. They believe the antibody or LAAB, known as AZD7442 and developed by AstraZeneca (Cambridge, UK) may offer immediate and long-term protection to people who have been recently exposed to the SARS-CoV-2 virus, to prevent them developing COVID-19. The other study, PROVENT, is looking at use of AZD7442 in people who may not respond to vaccination (for instance where someone has a compromised immune system) or are at increased risk of COVID-19 infection due to factors such as age and existing conditions. Antibodies are protein molecules that the body produces to help fight infections. Monoclonal antibodies are artificially produced in a laboratory and designed as possible medical treatments. They are designed to be injected directly into the body, unlike vaccines which ‘train’ the immune system itself to produce antibodies.

The LAABs have been engineered with AstraZeneca’s proprietary half-life extension technology to increase the durability of the therapy for six to 12 months following a single administration. The combination of two LAABs is also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus. In both PROVENT and STORM CHASER, researchers will assess whether the treatment reduces the risk of developing COVID-19 and/or reduces the severity of infection compared to placebo.

Key participant groups in the STORM CHASER trial will include healthcare workers, students who live in group accommodation, and patients who are exposed to anyone with the SARS-CoV-2 virus which causes COVID-19, as well as residents of long-term care facilities and industrial/military settings. Both trials are taking place at the Vaccine Research Centre at UCLH, which has been opened to help accelerate the development of new vaccines and treatments during the COVID-19 pandemic. As licensed vaccines become available to qualifying trial participants, a mechanism will be put in place to enable them to safely leave the study if deemed medically beneficial. Being a trial participant in one of the studies will not delay the process of receiving a vaccination and should not prevent patients being involved in other studies if they do develop an illness related to COVID-19.

“We know that this antibody combination can neutralize the virus, so we hope to find that giving this treatment via injection can lead to immediate protection against the development of COVID-19 in people who have been exposed – when it would be too late to offer a vaccine,” said UCLH virologist Dr. Catherine Houlihan who is leading the STORM CHASER study.

“We will be recruiting people who are older or in long-term care, and who have conditions such as cancer and HIV which may affect the ability of their immune system to respond to a vaccine. We want to reassure anyone for whom a vaccine may not work that we can offer an alternative which is just as protective,” said UCLH infectious diseases consultant Dr. Nicky Longley who is leading the UCLH portion of PROVENT.


Related Links:
University College London Hospitals NHS Foundation Trust
AstraZeneca


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
12-Channel ECG
CM1200B
New
Hospital Data Analytics Software
OR Companion
New
Hospital Bed
Alphalite

Print article

Channels

Surgical Techniques

view channel
Image: The surgical team and the Edge Multi-Port Endoscopic Surgical Robot MP1000 surgical system (Photo courtesy of Wei Zhang)

Endoscopic Surgical System Enables Remote Robot-Assisted Laparoscopic Hysterectomy

Telemedicine enables patients in remote areas to access consultations and treatments, overcoming challenges related to the uneven distribution and availability of medical resources. However, the execution... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.